JOPP, BC (July 8, 2021) – The International Society of Oncology Pharmacy Practitioners (ISOPP) is pleased to announce the publication of its “Position Statement: Role of the oncology pharmacy team in cancer care” in the Journal of Oncology Pharmacy Practice (JOPP).


ISOPP’s Publication on Biosimilars is published as a supplement in the Journal of Oncology Pharmacy Practice (JOPP).

ISOPP believes that oncology pharmacists have a crucial role to play in the implementation and optimal use of biosimilar medicines in clinical practice. To support oncology pharmacists in fulfilling this role, in 2018 the Secretariat of ISOPP formed a Biosimilars Task Force to review the available evidence, and to discuss the challenges and opportunities presented by the introduction of biosimilars into the oncology and supportive care setting and how these could be addressed.


The Journal of Oncology Pharmacy Practice was recently accepted into the Journal Citation Reports (JCR), and received its first ever Impact Factor in June 2017. This is a great testament to the commitment of the Editors and Editorial Board, who wish to thank the authors and reviewers for their dedication and hard work.

Subscribe to JOPP